Why the study?
Trastuzumab increases cardiac events in breast cancer, prompting evaluation of the cardiac safety of adding pertuzumab in HER2-positive early breast cancer.
Does pertuzumab plus trastuzumab increase the risk of cardiac events compared to trastuzumab alone in patients with early HER2-positive breast cancer?
Does pertuzumab plus trastuzumab increase the risk of cardiac events compared to trastuzumab alone in patients with early HER2-positive breast cancer?
Dual anti-HER2 blockade with pertuzumab and trastuzumab is safe from a cardiac perspective in early HER2-positive breast cancer, not increasing cardiac events compared to trastuzumab alone.
No takes yet. Share an insight, caveat, or question.
Supports dual anti-HER2 blockade without added cardiac risk in early HER2+ BC; confirms long-term cardiac safety of adjuvant pertuzumab plus trastuzumab.
Azambuja et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: